Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Reports | Stakeholder Opinions: Narcolepsy - Entry-point to a lucrative fatigue-associated market

Stakeholder Opinions: Narcolepsy - Entry-point to a lucrative fatigue-associated market

Narcolepsy is a chronic sleep disorder, which affects fewer than 500,000 sufferers across the seven major markets (7MM). The narcolepsy market value has grown considerably since 2004 to reach $230m in 2007 driven largely by the significant penetration of Provigil (modafinil; Cephalon) and Xyrem (sodium oxybate; Jazz Pharma) and the associated increase in the awareness of the disorder.

Patient Patient potential including disease definition, etiology, prevalence, diagnosis, and treatment guideline review.

Review of the key unmet needs in the treatment of narcolepsy as identified by key opinion leaders interviewed for the report.

Analysis of narcolepsy market IMS sales data from 2004 to 2007 for major marketed narcolepsy drugs: Provigil and Xyrem.

Pipeline analysis with detailed profile for Nuvigil (armodafinil, Cephalon) and the theory behind potential label expansions beyond narcolepsy.

Although generic versions of Cephalon's market leading treatment, Provigil (modafinil), are expected to launch in 2012, Datamonitor expects Cephalon to retain a significant position in the narcolepsy market by switching patients over from Provigil to its follow-up product, Nuvigil (armodafinil).

Despite Xyrem's (sodium oxybate) proven efficacy and its broader narcolepsy coverage than Provigil, Xyrem's sales continue to be limited because of its black box warning, restricted distribution and comparatively high price.

Targeting narcolepsy as a primary indication and then expanding Provigil's label coverage to other sleep disorders has proven commercially successful for Cephalon. Datamonitor believes companies could take this strategy a step further by using narcolepsy as an entry point to access the broader fatigue- or sleepiness-associated market.

Quantify the narcolepsy market value in the US, 5EU and Japan and identify the drivers and resistors in this market.

Understand key opinion leader (KOL) views on topical issues in the current and future treatment of narcolepsy and associated disorders.

Appreciate the potential of off-label prescribing and indication expansions for treatments possessing narcolepsy as the primary indication.

Publication: 39783
Library Code: DMHC2475
Type: Report
Format: PDF & SlidePack
Pages: 105

Table of Contents
Price: $3,800.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions